Article 3 : Quick pill
Why in News: The government amended the New Drugs and Clinical Trials Rules, 2019, replacing mandatory test licences with a prior-intimation system to ease pharma research, speed up drug development, reduce approval timelines, and support India’s goal of becoming a global pharmaceutical hub.
Key Details:
- Mandatory test licences scrapped for non-commercial drug manufacture.
- Prior intimation to CDSCO through the SUGAM Portal made sufficient.
- Drug synthesis allowed after online acknowledgement of notice.
- Expected three-month reduction in drug development timelines.
- Low-risk bioavailability and bioequivalence studies allowed post-intimation.
- Approval time for psychotropic and narcotic drugs cut from 90 to 45 days.
- Emphasis on documentation and GMP compliance despite relaxed licensing.
- Reform aimed at improving ease of doing business and innovation speed.
Policy Rationale and Objective
- The government has scrapped mandatory test licences for manufacturing small quantities of drugs meant solely for research and testing.
- The reform aims to reduce regulatory bottlenecks that often delay pharmaceutical innovation.
- This move aligns with the broader objective of improving ease of doing business in the pharma sector.
Key Changes in Drug Regulation Framework
- Amendments to the New Drugs and Clinical Trials Rules, 2019 replace licence requirements with a prior-intimation mechanism.
- Drug developers can begin non-commercial manufacture after informing the CDSCO through the SUGAM Portal.
- Once the notice of intent is acknowledged online, research-only drug synthesis can commence.
Expected Benefits of the Reform
- The government expects drug development timelines to reduce by at least three months, especially in a post-COVID environment where speed is critical.
- Certain low-risk bioavailability and bioequivalence studies can now begin with online intimation alone.
- For drugs still requiring licences, such as psychotropic and narcotic substances, approval timelines are cut from 90 to 45 days.
- A paperless system reduces delays, costs, and administrative inefficiencies.
Safeguards and Compliance Requirements
- Manufacturers must document and file all processes in strict adherence to regulatory rules.
- The reform does not dilute responsibility for Good Manufacturing Practices (GMP) compliance.
Concerns and Risks
- Faster approvals may risk quality control lapses if regulatory oversight weakens.
- Past incidents, such as cough syrup-related deaths, highlight the dangers of poor pharmaceutical supervision.
- Speed should not come at the cost of drug safety and efficacy.
Way Forward
- Establish post-intimation inspections to ensure strict adherence to GMP norms.
- Strengthen digital surveillance and audit mechanisms on the SUGAM Portal.
- Enhance accountability and penalties for quality violations.
- Invest in regulatory capacity building for CDSCO officials.
- Balance innovation facilitation with robust patient safety safeguards.
Conclusion
The removal of the licence-raj-style regulatory barrier marks a progressive step toward accelerating pharmaceutical research and positioning India as a global drug innovation hub. While the reform promises faster development, reduced costs, and potential life-saving outcomes, its success ultimately depends on maintaining uncompromising quality standards. Speed in drug development is valuable, but without vigilant oversight and enforcement, it risks undermining public trust and patient safety making balanced regulation the real test of this reform.
Prelims Question:
Which of the following is/are features of the new prior-intimation mechanism for drug research?
- Intimation must be submitted through the SUGAM Portal.
- It applies only to commercial-scale drug manufacturing.
- Drug synthesis can begin after online acknowledgement.
Select the correct answer using the code below:
- 1 and 3 only
- 1 only
- 2 and 3 only
- 1, 2 and 3
Answer: a